泰它西普治疗自身免疫性疾病研究进展
Advances in the treatment of autoimmune diseases with telitacicept
秦蕾 1吕凤艺 2王晓庆3
作者信息
- 1. 山东省第二人民医院风湿免疫科,山东济南 250022
- 2. 山东第一医科大学附属省立医院风湿免疫科,山东济南 250021
- 3. 高密市人民医院风湿免疫科,山东高密 261500
- 折叠
摘要
B细胞和体液免疫在自身免疫性疾病(autoimmune disease,AID)的发生发展中起着重要作用.B细胞活化因子(B cell activating factor,BAFF)和A增殖诱导配体(A proliferation-inducing ligand,APRIL)是维持B细胞库和体液免疫所必需的.泰它西普(telitacicept)是APRIL及BAFF受体穿膜蛋白活化物与免疫球蛋白G的Fc段融合蛋白,可用于治疗AID.现探讨泰它西普作用机制及其在系统性红斑狼疮(systemic lupus erythematosus)、自身免疫性肾病(autoimmune nephropathy)、视神经脊髓炎谱系疾病(neuromyelitis optica spectrum disorder)及原发性干燥综合征(primary Sjogren's syndrome)等 AID 中的治疗进展,旨在为临床用药提供一定参考.
Abstract
B cell and humoral immunity play an important role in the occurrence and development of autoimmune disease(AID).B cell activating factor(BAFF)and A proliferation-inducing ligand(APRIL)are necessary for the maintenance of B cell bank and humoral immunity.Telitacicept is a fusion protein of the Fc segment of APRIL and BAFF receptor transmembrane protein activator and immunoglobulin G,which can be used to treat AID.This article discussed the mechanism of action of telitacicept and its progress in the treatment of AID,including systemic lupus erythematosus,autoimmune nephropathy,neuromyelitis optica spectrum disorder and primary Sjogren's syndrome,in order to provide some reference for clinical use.
关键词
泰它西普/自身免疫性疾病/可溶性受体融合蛋白Key words
telitacicept/autoimmune disease/soluble receptor fusion protein引用本文复制引用
出版年
2024
NETL
NSTL
万方数据